Patented Medicines (Notice of Compliance) Regulations

Version of section 5 from 2006-03-22 to 2006-10-04:

  •  (1) Where a person files or has filed a submission for a notice of compliance in respect of a drug and compares that drug with, or makes reference to, another drug for the purpose of demonstrating bioequivalence on the basis of pharmaceutical and, where applicable, bioavailability characteristics and that other drug has been marketed in Canada pursuant to a notice of compliance issued to a first person and in respect of which a patent list has been submitted, the person shall, in the submission, with respect to each patent on the register in respect of the other drug,

    • (a) state that the person accepts that the notice of compliance will not issue until the patent expires; or

    • (b) allege that

      • (i) the statement made by the first person pursuant to paragraph 4(2)(c) is false,

      • (ii) the patent has expired,

      • (iii) the patent is not valid, or

      • (iv) no claim for the medicine itself and no claim for the use of the medicine would be infringed by the making, constructing, using or selling by that person of the drug for which the submission for the notice of compliance is filed.

  • (1.1) Subject to subsection (1.2), where subsection (1) does not apply and where a person files or has filed a submission for a notice of compliance in respect of a drug that contains a medicine found in another drug that has been marketed in Canada pursuant to a notice of compliance issued to a first person and in respect of which a patent list has been submitted, the person shall, in the submission, with respect to each patent included on the register in respect of the other drug containing the medicine, where the drug has the same route of administration and a comparable strength and dosage form,

    • (a) state that the person accepts that the notice of compliance will not issue until the patent expires; or

    • (b) allege that

      • (i) the statement made by the first person pursuant to paragraph 4(2)(c) is false,

      • (ii) the patent has expired,

      • (iii) the patent is not valid, or

      • (iv) no claim for the medicine itself and no claim for the use of the medicine would be infringed by the making, constructing, using or selling by that person of the drug for which the submission for the notice of compliance is filed.

  • (1.2) Where a person referred to in subsection (1.1) has served, in accordance with paragraph (3)(b) or (c), a notice of allegation on a first person in respect of a patent included on the register, the person is not required to serve a notice of allegation in respect of the same submission, the same allegation and the same patent on another first person.

  • (2) Where, after a second person files a submission for a notice of compliance but before the notice of compliance is issued, a patent list or an amendment to a patent list is submitted in respect of a patent pursuant to subsection 4(4), the second person shall amend the submission to include, in respect of that patent, the statement or allegation that is required by subsection (1) or (1.1), as the case may be.

  • (3) Where a person makes an allegation pursuant to paragraph (1)(b) or (1.1)(b) or subsection (2), the person shall

    • (a) provide a detailed statement of the legal and factual basis for the allegation;

    • (b) if the allegation is made under any of subparagraphs (1)(b)(i) to (iii) or (1.1)(b)(i) to (iii), serve a notice of the allegation on the first person;

    • (c) if the allegation is made under subparagraph (1)(b)(iv) or (1.1)(b)(iv),

      • (i) serve on the first person a notice of the allegation relating to the submission filed under subsection (1) or (1.1) at the time that the person files the submission or at any time thereafter, and

      • (ii) include in the notice of allegation a description of the dosage form, strength and route of administration of the drug in respect of which the submission has been filed; and

    • (d) serve proof of service of the information referred to in paragraph (b) or (c) on the Minister.

  • SOR/98-166, ss. 4, 9
  • SOR/99-379, s. 2
Date modified: